OOS, OOT, OOC, and OOSC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

OOS, OOT, OOC, and OOSC
Current GMPs demand full understandng of out-of-control concepts. This article contains bonus material.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 46-47

cGMP perspective

That said, the cGMPs still call for companies to have firm control of their processes, statistical or otherwise. Being out-of-statistical-control, but within specifications is not acceptable from a cGMP perspective because there is a higher probability of manufacturing defective product. Companies are required to show continuing due diligence, provide data and analysis to prove that the process is being brought into a state of statistical control, or provide a scientific and statistical study to explain why it cannot be controlled.

To summarize, for control charts, practical significance and OOT go together, and statistical significance and statistical control go together. There are four possible combinations, the control charts for which can be viewed together at http://PharmTech.com/ controlcharts:


Figure 1: Not out-of-trend and not out-of-statistical-control.
1. Not OOT and not OOSC: the ideal situation (see Figure 1)







Figure 2: Out-of-statistical-control but not out-of-trend. Fails Western Electric rule number 2 (7 points on the same side of the center line).
2. Not OOT but OOSC: cannot yet see a practical change, but failed one or more WE8 rules (see Figure 2)







Figure 3: Not out-of-statistical-control but is out-of-trend. Passes all 8 Western Electric rules.
3. OOT but not OOSC: can see a practical change that is not yet statistically significant (see Figure 3)







Figure 4: Out-of-trend and out-of-statistical-control.
4. OOT and OOSC: can see a practical change that is statistically significant (see Figure 4).






Finally, any of these four combinations can be OOS or not OOS as the specification concept is independent of trend (practical significance) and statistical significance.

Lynn D. Torbeck is a statistician at Torbeck and Assoc., 2000 Dempster Plaza, Evanston, IL 60202, tel. 847.424.1314,
, http://www.torbeck.org/.

References

1. FDA, Guidance for Industry: Process Validation: General Principles and Practices (Rockville, MD, Nov. 2008)

2. FDA, Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production (Rockville, MD, Oct. 2006)

3. L.D. Torbeck, Pharm. Technol. 34 (3), 21–23 (1999)

4. Matrixx Initiatives, Inc. v. Siracusano, 131 S. Ct. 1309, (2011)

5. L.D. Torbeck, Pharm. Technol. 34 (3), 76 (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here